U.S. markets closed

Scopus BioPharma Inc. (SCPS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
3.9900-0.0600 (-1.48%)
At close: 4:00PM EDT
3.9400 -0.05 (-1.25%)
After hours: 07:12PM EDT

Scopus BioPharma Inc.

420 Lexington Avenue
Suite 300
New York, NY 10170
United States
212 479 2513

Full Time Employees1

Key Executives

NameTitlePayExercisedYear Born
Mr. Robert J. GibsonVice Chairman, Sec. & Treasurer180kN/AN/A
Mr. Ira Scott GreenspanSr. Advisor & Director180kN/A1959
Dr. Alan M. Horsager Ph.D.PresN/AN/AN/A
Mr. David SilbergSr. AdvisorN/AN/A1949
Alan D. Horsager Ph.D.Pres?of?Immuno-Oncology and Pres & CEO of Olimmune Inc.N/AN/A1973
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Scopus BioPharma Inc., a biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. Its lead development programs are immuno-oncology gene therapy for the treatment of various cancers, which include CO-sTiRNA, a STAT3 inhibitor gene therapy that drives tumor cell growth and anti-tumor immune suppression; and MRI-1867, a cannabinoid-1 receptor inverse agonist and inhibitor of inducible nitric oxide synthase for the treatment of systemic sclerosis. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Corporate Governance

Scopus BioPharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.